Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: An example from the Canadian Cancer Trials Group CO.17 trial

Jeffrey S. Hoch, Annette Hay, Wanrudee Isaranuwatchai, Kednapa Thavorn, Natasha B. Leighl, Dongsheng Tu, Logan Trenaman, Carolyn S. Dewa, Chris O'Callaghan, Joseph Pater, Derek Jonker, Bingshu E. Chen, Nicole Mittmann

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.

Original languageEnglish (US)
Article number552
JournalBMC Cancer
Volume19
Issue number1
DOIs
StatePublished - Jun 7 2019

Keywords

  • Cost-effectiveness
  • Economic evaluation
  • Net benefit regression

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: An example from the Canadian Cancer Trials Group CO.17 trial'. Together they form a unique fingerprint.

Cite this